Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 408

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke

Open access
LeCouffe, Natalie E., Kappelhof, Manon, Treurniet, Kilian M., Rinkel, Leon A., Bruggeman, Agnetha E., Berkhemer, Olvert A., Wolff, Lennard, van Voorst, Henk, Tolhuisen, Manon L., Dippel, Diederik W.J., van der Lugt, Aad, van Es, Adriaan C.G.M., Boiten, Jelis, Lycklama à Nijeholt, Geert J., Keizer, Koos, Gons, Rob A.R., Yo, Lonneke S.F., van Oostenbrugge, Robert J., van Zwam, Wim H., Roozenbeek, Bob, van der Worp, H. Bart, Lo, Rob T.H., van den Wijngaard, Ido R., de Ridder, Inger R., Costalat, Vincent, Arquizan, Caroline, Lemmens, Robin, Demeestere, Jelle, Hofmeijer, Jeannette, Martens, Jasper M., Schonewille, Wouter J., Vos, Jan-Albert, Uyttenboogaart, Maarten, Bokkers, Reinoud P.H., van Tuijl, Julia H., Kortman, Hans, Schreuder, Floris H.B.M., Boogaarts, Hieronymus D., de Laat, Karlijn F., van Dijk, Lukas C., den Hertog, Heleen M., van Hasselt, Boudewijn A.A.M., Brouwers, Paul J.A.M., Bulut, Tomas, Remmers, Michel J.M., van Norden, Anouk, Imani, Farshad, Rozeman, Anouk D., Elgersma, Otto E.H., Desfontaines, Philippe, Brisbois, Denis, Samson, Yves, Clarençon, Frédéric, Krietemeijer, G. Menno, Postma, Alida A., van Doormaal, Pieter-Jan, van den Berg, René, van der Hoorn, Anouk, Beenen, Ludo F.M., Nieboer, Daan, Lingsma, Hester F., Emmer, Bart J., Coutinho, Jonathan M., Majoie, Charles B.L.M., Roos, Yvo B.W.E.M.·2021·New England Journal of Medicine

Abstract

BACKGROUND: The value of administering intravenous alteplase before endovascular treatment (EVT) for acute ischemic stroke has not been studied extensively, particularly in non-Asian populations. METHODS: We performed an open-label, multicenter, randomized trial in Europe involving patients with stroke who presented directly to a hospital that was capable of providing EVT and who were eligible for intravenous alteplase and EVT. Patients were randomly assigned in a 1:1 ratio to receive EVT alone or intravenous alteplase followed by EVT (the standard of care). The primary end point was functional outcome on the modified Rankin scale (range, 0 [no disability] to 6 [death]) at 90 days. We assessed the superiority of EVT alone over alteplase plus EVT, as well as noninferiority by a margin of 0.8 for the lower boundary of the 95% confidence interval for the odds ratio of the two trial groups. Death from any cause and symptomatic intracerebral hemorrhage were the main safety end points. RESULTS: The analysis included 539 patients. The median score on the modified Rankin scale at 90 days was 3 (interquartile range, 2 to 5) with EVT alone and 2 (interquartile range, 2 to 5) with alteplase plus EVT. The adjusted common odds ratio was 0.84 (95% confidence interval [CI], 0.62 to 1.15; P = 0.28), which showed neither superiority nor noninferiority of EVT alone. Mortality was 20.5% with EVT alone and 15.8% with alteplase plus EVT (adjusted odds ratio, 1.39; 95% CI, 0.84 to 2.30). Symptomatic intracerebral hemorrhage occurred in 5.9% and 5.3% of the patients in the respective groups (adjusted odds ratio, 1.30; 95% CI, 0.60 to 2.81). CONCLUSIONS: In a randomized trial involving European patients, EVT alone was neither superior nor noninferior to intravenous alteplase followed by EVT with regard to disability outcome at 90 days after stroke. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by the Collaboration for New Treatments of Acute Stroke consortium and others; MR CLEAN-NO IV ISRCTN number, ISRCTN80619088.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2107727

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 408

Metadata

Authors
LeCouffe, N. E., Kappelhof, M., Treurniet, K. M., Rinkel, L. A., Bruggeman, A. E., Berkhemer, O. A., Wolff, L., van Voorst, H., Tolhuisen, M. L., Dippel, D. W. J., van der Lugt, A., van Es, A. C. G. M., Boiten, J., Lycklama à Nijeholt, G. J., Keizer, K., Gons, R. A. R., Yo, L. S. F., van Oostenbrugge, R. J., van Zwam, W. H., Roozenbeek, B., van der Worp, H. B., Lo, R. T. H., van den Wijngaard, I. R., de Ridder, I. R., Costalat, V., Arquizan, C., Lemmens, R., Demeestere, J., Hofmeijer, J., Martens, J. M., Schonewille, W. J., Vos, J.-A., Uyttenboogaart, M., Bokkers, R. P. H., van Tuijl, J. H., Kortman, H., Schreuder, F. H. B. M., Boogaarts, H. D., de Laat, K. F., van Dijk, L. C., den Hertog, H. M., van Hasselt, B. A. A. M., Brouwers, P. J. A. M., Bulut, T., Remmers, M. J. M., van Norden, A., Imani, F., Rozeman, A. D., Elgersma, O. E. H., Desfontaines, P., Brisbois, D., Samson, Y., Clarençon, F., Krietemeijer, G. M., Postma, A. A., van Doormaal, P.-J., van den Berg, R., van der Hoorn, A., Beenen, L. F. M., Nieboer, D., Lingsma, H. F., Emmer, B. J., Coutinho, J. M., Majoie, C. B. L. M., & Roos, Y. B. W. E. M.
Venue
New England Journal of Medicine
Published
2021-11-11
Volume
385
Issue
20
Pages
1833-1844
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3211535388
Cited by
408
References
20
FWCI
46.11
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke. https://app.cochat.ai/papers/10.1056/nejmoa2107727
The paper
LeCouffe, N. E., Kappelhof, M., Treurniet, K. M., Rinkel, L. A., Bruggeman, A. E., Berkhemer, O. A., Wolff, L., van Voorst, H., Tolhuisen, M. L., Dippel, D. W. J., van der Lugt, A., van Es, A. C. G. M., Boiten, J., Lycklama à Nijeholt, G. J., Keizer, K., Gons, R. A. R., Yo, L. S. F., van Oostenbrugge, R. J., van Zwam, W. H., . . . Roos, Y. B. W. E. M. (2021). A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2107727

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.